Inhibition of platelet function by aspirin or Clopidogrel is a cornerstone of treatment of peripheral vascular disease. development evaluation test of platelet function has to highlight an inadequate response to clopidogrel in a large proportion of patients. the increase doses of clopidogrel, the use of prasugrel, a third-generation thienopyridine, the association cilostazol reduces the proportion of patients platelet response "inadequate." If the benefit a strategy of aggressive antiplatelet clearly demonstrated in high-risk situations thrombosis such as coronary angioplasty, no data does at present to extrapolate that attitude to care for patients arteritis.